Related references
Note: Only part of the references are listed.Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Hsin-Pei Shih et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
The Proposal to Lower P Value Thresholds to .005
John P. A. Ioannidis
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
The FDA Breakthrough-Drug Designation - Four Years of Experience
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Abstracts from Plenary and Keynote Speakers
Public Health Genomics (2018)
The druggable genome and support for target identification and validation in drug development
Chris Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges
Lavinia Paternoster et al.
PLOS GENETICS (2017)
Impact of Selection Bias on Estimation of Subsequent Event Risk
Yi-Juan Hu et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2017)
The reproducibility of research and the misinterpretation of p-values
David Colquhoun
ROYAL SOCIETY OPEN SCIENCE (2017)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Joshua C. Denny et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 17 (2016)
Selecting instruments for Mendelian randomization in the wake of genome-wide association studies
Daniel I. Swerdlow et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
Disciplined approach to drug discovery and early development
Robert M. Plenge
SCIENCE TRANSLATIONAL MEDICINE (2016)
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Thomas J. Hwang et al.
JAMA INTERNAL MEDICINE (2016)
Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits
Andrew Bakshi et al.
SCIENTIFIC REPORTS (2016)
How Good Is Evidence from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?
Huseyin Naci et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
HMG-COENZYME A REDUCTASE INHIBITION, TYPE 2 DIABETES, AND BODYWEIGHT: EVIDENCE FROM GENETIC ANALYSIS AND RANDOMISED TRIALS
D. Swerdlow et al.
ATHEROSCLEROSIS (2015)
Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations
Ernst R. Berndt et al.
HEALTH AFFAIRS (2015)
The support of human genetic evidence for approved drug indications
Matthew R. Nelson et al.
NATURE GENETICS (2015)
A gene-based association method for mapping traits using reference transcriptome data
Eric R. Gamazon et al.
NATURE GENETICS (2015)
The fickle P value generates irreproducible results
Lewis G. Halsey et al.
NATURE METHODS (2015)
FROM THE ANALYST'S COUCH What does it take to produce a breakthrough drug?
Dirk Calcoen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
Malcolm R. Macleod et al.
PLOS BIOLOGY (2015)
Towards a sustainable system of drug development
Ellen H. M. Moors et al.
DRUG DISCOVERY TODAY (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
An investigation of the false discovery rate and the misinterpretation of p-values
David Colquhoun
ROYAL SOCIETY OPEN SCIENCE (2014)
Phase II and Phase III attrition rates 2011-2012
John Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Pleiotropy in complex traits: challenges and strategies
Nadia Solovieff et al.
NATURE REVIEWS GENETICS (2013)
Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments
Valerie C. Henderson et al.
PLOS MEDICINE (2013)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Making medicines evergreen
Andrew W. Hitchings et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Phase II failures: 2008-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Believe it or not: how much can we rely on published data on potential drug targets?
Florian Prinz et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
TRIAL WATCH Phase III and submission failures: 2007-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
A Versatile Gene-Based Test for Genome-wide Association Studies
Jimmy Z. Liu et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry
Juan P. Casas et al.
CIRCULATION (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Mendelian Randomization Nature's Randomized Trial in the Post-Genome Era
George Thanassoulis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lessons from 60 years of pharmaceutical innovation
Bernard Munos
NATURE REVIEWS DRUG DISCOVERY (2009)
The state of innovation in drug development
I. Kola
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Estimation of significance thresholds for genomewide association scans
Frank Dudbridge et al.
GENETIC EPIDEMIOLOGY (2008)
Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?
Shah Ebrahim et al.
HUMAN GENETICS (2008)
Clinical attrition due to biased preclinical assessments of potential efficacy
Mark D. Lindner
PHARMACOLOGY & THERAPEUTICS (2007)
Comparison of treatment effects between animal experiments and clinical trials: systematic review
Pablo Perel et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Why most published research findings are false
JPA Ioannidis
PLOS MEDICINE (2005)
Sifting the evidence - what's wrong with significance tests?
JAC Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)